Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Large granular lymphocyte (LGL) leukemia is characterized by the expansion of antigen-activated cytotoxic T lymphocytes. These leukemic cells are resistant to Fas-mediated apoptosis despite expressing high levels of Fas. We found that leukemic LGL from 19 patients displayed high levels of activated STAT3. Treatment of leukemic LGL with the JAK-selective tyrosine kinase inhibitor AG-490 induced apoptosis with a corresponding decrease in STAT-DNA binding activity. Moreover, using an antisense oligonucleotide approach to diminish STAT3 expression, we found that Fas sensitivity was restored in leukemic LGL. AG-490-induced apoptosis in leukemic LGL was independent of Bcl-xL or Bcl-2 expression. However, we found that the Bcl-2-family protein Mcl-1 was significantly reduced by AG-490 treatment. Activated STAT3 was shown to bind an SIE-related element in the murine mcl-1 promoter. Using a luciferase reporter assay, we demonstrated that v-src overexpression in NIH3T3 induced STAT3-dependent transcriptional activity from the mcl-1 promoter and increased endogenous Mcl-1 protein levels. We conclude that STAT3 activation contributed to accumulation of the leukemic LGL clones. These findings suggest that investigation should focus on novel strategies targeting STAT3 in the treatment of LGL leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other inhibition strategies include the introduction of antisense oligonucleotides, as in the case of the Isis Pharmaceuticals, Inc/AstraZeneca drug in clinical development, designed to cause degradation of STAT3 mRNA or prevent its translation via complementary base pairing, thereby reducing total STAT3 protein levels.105”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the STAT3 protein in the peripheral blood mononuclear cell extracts isolated from patients with large granular lymphocyte leukemia has been reported to bind to the murine SIE motif (9).”
The cited source says what the claim attributes to it.
In the citing paper
“IL-6 plays a significant role in inducing tumor growth as it interacts with the receptor, JAK, to induce STAT-3 activation. STAT-3 then activates oncogenes such as MCL-1 (29) and upregulates genes involved in proliferation such as Cyclin-D1 (30). These activities result in the induction of cancer cell proliferation.”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979 · cited 2×
“Proteolytic cleavage and activation of a cascade of caspases (death proteases) mediate the cleavage of cellular targets, resulting in programmed cell death (38, 39).”
BackgroundLymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., & Nagata, S. (1992) · Nature · doi:10.1038/356314a0 · Cited by 2,885 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundBromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citationGeneralized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand
Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., & Nagata, S. (1994) · Cell · doi:10.1016/0092-8674(94)90375-1 · Cited by 1,528 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · cited 11×
“Transfection of the indicated plasmids into NIH3T3 cells was performed using CaP04, as described previously (28). pM-v-src and pSG5-STAT3β are plasmid vectors expressing v-src and a dominant negative mutant of STAT3, respectively.”
MethodInfluentialSelf-citationInhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897 · cited 2×
“Therefore, we used a tyrphostin inhibitor (AG-490) selective for the JAKfamily tyrosine kinases to determine whether inhibition of the pathway upstream of STAT activation would affect apoptosis in LGL leukemia cells (32).”
MethodWakao, H., Gouilleux, F., & Groner, B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06495.x · Cited by 826 · cited 2×
“The degree of binding was determined by electrophoretic analysis on a 5% native polyacrylamide gel as described previously (19, 31).”
BackgroundMethod
Cited by
Items 501–600 of 643
Large granular lymphocyte cells and immune dysregulation diseases – the chicken or the egg?
Langerak, A. W., & Assmann, J. L. J. C. (2018) · Haematologica · doi:10.3324/haematol.2017.186338 · Cited by 6
“In addition, specific inhibition of JAK family kinases with the AG-490 tyrosine kinase inhibitor has been demonstrated to induce apoptosis of LGL leukemia cells in vitro and antisense oligonucleotide therapy to inhibit STAT3 activation, which has been shown to restore FAS sensitivity in LGL leukemia cells.(17) However…”
BackgroundInhibition of miR-20a promotes neural stem cell survival under oxidative stress conditions
Arzhanov, I., Klassen, R. A., Valihrach, L., & Romanyuk, N. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1601101 · Cited by 5
Large granular lymphocytic leukemia cured by allogeneic stem cell transplant: a case report
Carey, E. T., Ward, N., & Abdul‐Hay, M. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03447-y · Cited by 5
“In particular, signal transducer and activator of transcription factor 3 (STAT3) is a mutation that has been described in approximately one-third to half of LGL leukemia cases [3, 13, 14].”
BackgroundCurcumin analogue, A13, exhibits anti-leukemia effect via inhibiting STAT3
Weng, Q., Ren, L., Guo, L., Hu, Y., Zhou, H., Bao, Y., Chen, L., Liang, G., Wang, Y., & Ruan, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-4861-0 · Cited by 5
Moosic, K. B., Olson, T. L., Freijat, M., Khalique, S., Hamele, C. E., Shemo, B. C., Boodoo, J., Baker, W. D. C., Khurana, G., Schmachtenberg, M. W., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1466276 · Cited by 4
Self-citationGorodetskiy, V. R., Vasilyev, V. I., Sidorova, Y. V., Вениаминовна, Б. Б., Александровна, К. Н., Vagida, M. S., Ryzhikova, N. V., & Sudarikov, A. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113345 · Cited by 4
“Constitutive activation of the STAT3 pathway is a hallmark of T-LGL leukemia pathobiology [13,43], and STAT3 mutations were detected in 27–72% of patients with T-LGL leukemia [13,44–46].”
Mature T-cell leukemias: Molecular and Clinical Aspects
Bailey, N. G., & Elenitoba‐Johnson, K. S. J. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0288-8 · Cited by 6
Pan, Y., ZHANG, L., Zhang, X., & Liu, R. (2014) · Oncology Reports · doi:10.3892/or.2014.3623 · Cited by 4
“However, the constitutive activation of STAT3 and its overexpression have been detected in numerous human cancer cell lines and primary tumors, such as multiple myelomas, head and neck and ovarian cancer, leukemia, prostate, pancreatic, lung, gastric, as well as breast cancer (9-17).”
BackgroundRetractedZhang, J., Yü, P., Zhao, Q., Guo, R., Shan, J., Liu, F., Wang, J., & Zhang, Y. (2022) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2022.101804 · Cited by 4
Self-citation[Chinese expert consensus on the diagnosis and treatment of acquired pure red cell aplasia (2020)].
(2020) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2020.03.001 · Cited by 4
“[35] Epling-Burnette PK, Liu JH, Catlett-Falcone R, et al.”
Early changes in gene expression profiles in AML patients during induction chemotherapy
Falk, I. J., Sundkvist, M., Björn, N., Gréen, H., & Lotfi, K. (2022) · BMC Genomics · doi:10.1186/s12864-022-08960-4 · Cited by 4
The Radiosensitizing Potentials of Silymarin/Silibinin in Cancer: A Systematic Review
Gupta, J., Jalil, A. T., Muedii, Z. A.-H. R., Aminov, Z., Alsaikhan, F., Ramírez‐Coronel, A. A., Ramaiah, P., & Farhood, B. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673248404231006052436 · Cited by 5
Management of T‐cell malignancies: Bench‐to‐bedside targeting of epigenetic biology
Sabzevari, A., Ung, J., Craig, J. W., Jayappa, K. D., Pal, I., Feith, D. J., Loughran, T. P., & O’Connor, O. A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70001 · Cited by 9
“…by another commonly found mutation in STAT3 leads to leukemogenesis, in this case, LGLL. LGLL is primarily driven by constitutive STAT3 activation, 71 which is derived from a combination of highly recurrent STAT3 hotspot mutations, 72,73 LGLL cytokine signaling, and indirect epigenetic silencing…”
Self-citationCousens, L. P., Goulette, F. A., & Darnowski, J. W. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.1.320 · Cited by 4
Apoptosis, senescence and cancer (cancer drug discovery and development)
Young, A. R. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604944 · Cited by 4
Blocked addiction to IL-15 for treating T-LGLL
Prince, H. M. (2023) · Blood · doi:10.1182/blood.2023021476 · Cited by 4
Derepressing of STAT3 and USP7 contributes to resistance of DLBCL to EZH2 inhibition
He, C., Zhou, W., Jin, X., & Zhou, H. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20650 · Cited by 3
“STAT3 as a transcription factor targets to anti-apoptotic genes, such as Mcl-1, Survivin, and BCL2 [ [30,33,34]].”
BackgroundChueh, F., Cronk, R. J., Alsuwaidan, A. N., Mallers, T. M., Jaiswal, M. K., Beaman, K. D., & Yu, C. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.810740 · Cited by 3
Molecular Cloning of Canine Mcl-1 Gene and its Expression in Tumor Cell Lines
Sano, J., Oguma, K., Kano, R., & Hasegawa, A. (2004) · Journal of Veterinary Medical Science · doi:10.1292/jvms.66.709 · Cited by 3
Mel, S. D., Wong, B., Gole, L., Ng, S., Koay, E. S.-C., Siong, C. N. W., Seet, J. E., Wee, A., Chng, W. J., & Tan, L. K. (2015) · Journal of Hematology · doi:10.14740/jh223w · Cited by 3
“It is important to further clarify the underlying genetic abnormalities in STAT3 mutation negative LGL, especially those with the rare aggressive variant like ours who had a suboptimal response to conventional chemotherapy [19].”
BackgroundSTAT3 and Transactivation of Steroid Hormone Receptors
Lee, S. O., & Gao, A. C. (2005) · Vitamins and hormones · doi:10.1016/s0083-6729(05)70011-x · Cited by 3
Nucleic Acid Therapies for Cancer Treatment
Vogl, D. T., & Gewirtz, A. M. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-337-0_17 · Cited by 3
“Preclinical studies implicate persistent STAT3 signaling in malignant transformation, through increased expression of genes associated with proliferation, cell survival, and angiogenesis (113,114) .A2 -MOE antisense oligonucleotide against STAT3 (ISIS 345794) results in reduced STAT3 levels in cell lines and xenograft…”
BackgroundSTAT Proteins as Molecular Targets for Cancer Therapy
Buettner, R., Kortylewski, M., Pardoll, D. M., Yu, H., & Jove, R. (2003) · Springer eBooks · doi:10.1007/978-94-017-3000-6_41 · Cited by 3
Self-citationGupta, S. R. R., Mittal, P., Kundu, B., Singh, A. K., & Singh, I. K. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2268176 · Cited by 2
“The STAT3 pathway regulates members of the BCL-2 family, including BCL-2A1/BFL1 (Bhattacharya et al., 2005; Choi et al., 2009; Epling-Burnette et al., 2001; Hata et al., 2015; Kang et al., 2015).”
Calabretto, G., Binatti, A., Teramo, A., Buratin, A., Barilà, G., Gasparini, V. R., Vicenzetto, C., Gaffo, E., Rampazzo, E., Orsi, S., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02708-1 · Cited by 2
“Several studies [13 – 15] have highlighted the crucial role of the JAK-STAT pathway in LGL survival network and its link with the disease clinical manifestations, addressing the molecular alterations that lead to its aberrant activation.”
Tosello, V., Bongiovanni, D., Martino, L. D., Franchin, C., Zanovello, P., Arrigoni, G., & Piovan, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126384 · Cited by 2
“The specific apoptosis was calculated as previously described [46].”
MethodCho, Y. M., Anderson, E., Guevara, S., Miyara, S. J., Iqbal, A., Aronsohn, J., Molmenti, E. P., Mumford, J. M., Keber, B., Farideh, Z.-Z., et al. (2021) · Journal of Clinical Rheumatology and Immunology · doi:10.1142/s2661341722720026 · Cited by 3
T-sejtes nagy granuláris lymphocytás leukémia ezer arca és sikeres kezelése
Kovács, S., Szabó, Z., Iványi, J. L., Szendrei, T., & Plander, M. (2022) · Hematológia–Transzfuziológia · doi:10.1556/2068.2022.00147 · Cited by 2
Lissina, A., McLaren, J. E., Ilander, M. M., Andersson, E. I., Lewis, C., Clement, M., Herman, A., Ladell, K., Llewellyn‐Lacey, S., Miners, K. L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18062-x · Cited by 3
Role of STAT3 in Pancreatic Cancer: A Target for Therapy
Daddacha, W. B., Koyen, A. E., Schlafstein, A. J., & Yu, D. S. (2017) · Springer eBooks · doi:10.1007/978-981-10-6728-0_24 · Cited by 2
Бажанова, Е. Д., Molodtsov, V. N., Pavlov, K. I., Bazhanova, Y. D., Molodtzov, V. N., & Pavlov, K. I. (2006) · Morphology · doi:10.17816/morph.402446 · Cited by 2
Large Granular Lymphocyte Leukemia
Dürig, J. (2019) · Hematologic malignancies · doi:10.1007/978-3-030-11392-6_12 · Cited by 2
The RKIP and STAT3 Axis in Cancer Chemotherapy: Opposites Attract
Chatterjee, D., Sabo, E., Resnick, M. B., Yeung, K. C., & Chin, Y. E. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-474-2_10 · Cited by 2
“Similarly, the JAK tyrosine kinase inhibitor AG-490 can induce apoptosis while limiting STAT3 DNA binding [83].”
BackgroundTargeting the Apoptotic Machinery as a Potential Antileukemic Strategy
Mow, B. M. F., & Kaufmann, S. H. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-383-5_11 · Cited by 2
Leukämie mit großen granulären Lymphozyten
Teramo, A., Vicenzetto, C., Barilà, G., Calabretto, G., Gasparini, V. R., Semenzato, G., & Zambello, R. (2023) · Springer eBooks · doi:10.1007/978-3-031-22881-0_15 · Cited by 1
Gong, Y., Li, Y., Chen, X., Yang, H., Zhang, Y., He, G., & Fan, L. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05856-z · Cited by 1
“…studies have revealed an overactivation of STAT3 signaling in leukemic LGLs and underlay the application of JAK/STAT inhibitors in T-LGL leukemia [18 , 19], espe - cially in cases harboring STAT3 gain-of-function mutations, which account for 45–77% [ 20, 21 ] of T-LGL leukemia-associated PRCA.”
Self-citationFunctional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemia
Shumilov, E., Mazzeo, P., Trautmann, M., Levien, L., Menck, K., Richter, K., Markus, K., Ries, L., Haase, D. T., Oberle, E., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06230-3 · Cited by 1
“In addition, previous studies demonstrated that mutated STAT3 upregulates MCL-1 in T-LGLL [29].”
Hesperetin Induces Apoptosis of Human Gastric Adenocarcinoma Cells
Yang, J. Y., Kim, H. W., Woo, H. J., Kim, J. Y., Park, M., & Kim, S. (2025) · Journal of Experimental & Biomedical Sciences/Biomedical Science Letters · doi:10.15616/bsl.2025.31.2.137 · Cited by 1
Aptullahoğlu, E., & Kaygusuz, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178648 · Cited by 1
Molecular Biological Insights into Large Granular Lymphocyte Leukemia
Huang, Z., & Du, J. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1013745 · Cited by 1
Regulation of the Jak/STATs Pathways by Histone Deacetylases
Woods, D. M., Lienlaf, M., Sotomayor, E. M., Seto, E., & Villagra, A. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-8039-6_7 · Cited by 1
Бажанова, Е. Д., Molodtsov, V., & Павлов, К. И. (2007) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-008-0006-2 · Cited by 1
“According to published data, IA has different actions on the control of apoptosis [8, 9, 14].”
BackgroundRole and Regulation of Transcriptional Factors in Gastric Cancer
Neelapu, N. R. R. (2017) · Springer eBooks · doi:10.1007/978-981-10-6728-0_9 · Cited by 2
Mesa, R. A., & Kaufmann, S. H. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-322-6_6 · Cited by 1
Src protein tyrosine kinases in stress responses
Grishin, A., & Corey, S. J. (2002) · Korean Journal of Biological Sciences · doi:10.1080/12265071.2002.9647626 · Cited by 1
“…SFK include inhibition of BAD and transcriptional induction of Be 1-2, positive and negative apoptotic proteins, via ERK and RSK (Wang et al., 2001) and trans criptional induction of the Be 1-2 famify protein Mcl-1 together with the trans criptional activator STAT3 (Epling-Burnette et al., 2001).”
BackgroundBCL-XL as a tumour prognostic factor?
Karczmarek-Borowska, B., Zmorzyński, S., Filip, A. A., & Wojcierowski, J. (2010) · Współczesna Onkologia · doi:10.5114/wo.2010.972 · Cited by 1
Abdallah, D., Abdelmonsif, D. A., Moaaz, M., & Selimah, M. (2016) · International Journal of Advanced Research · doi:10.21474/ijar01/479 · Cited by 1
Phenocopies of inborn errors of immunity
Oksenhendler, É. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816768-7.00006-5 · Cited by 1
Large Granular Lymphocyte Leukemia
Dziewulska, K. H., Moosic, K. B., Cheon, H., Olson, K. C., Feith, D. J., & Loughran, T. P. (2021) · Wiley eBooks · doi:10.1002/9781119671336.ch14 · Cited by 1
Self-citationAltered epigenetics at the center of NK-LGL leukemia
Herling, M., & Wahnschaffe, L. (2021) · Blood · doi:10.1182/blood.2021011875 · Cited by 1
Strategies for Targeting the JAK ‐ STAT Pathway in Lymphoid Malignancies
Feith, D. J., Ung, J., Elghawy, O., Yue, P., Turkson, J., & Loughran, A. T. P. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch27 · Cited by 2
Self-citationAssmann, J. L. J. C., Vlachonikola, E., Kolijn, P. M., Agathangelidis, A., Pechlivanis, N., Papalexandri, A., Σταματόπουλος, Κ., Chatzidimitriou, A., & Langerak, A. W. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000929 · Cited by 1
Aptullahoğlu, E. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10834-3 · Cited by 1
“Its pharmacologic or genetic inhibition has been shown to downregulate key p53 downstream targets such as BCL-XL and MCL-1, while also interfering with STAT3-mediated immune evasion mechanisms [ 54, 55].”
Large Granular Lymphocyte Leukemia – From Molecular Pathogenesis to Targeted Therapy
Shah, M. V., & Loughran, T. P. (2012) · Springer eBooks · doi:10.1007/978-94-007-5028-9_16 · Cited by 1
Self-citationUnderstanding acquired resistance to Lapatinib in breast cancer cells
Tseng, J. (2010) · Digital Commons-TMC (Texas Medical Center) · Cited by 1
Constitutively Active STATs and Cellular Transformation
Dechow, T. N., & Bromberg, J. (2003) · Springer eBooks · doi:10.1007/978-94-017-3000-6_40 · Cited by 1
Physiological and Pharmacological Regulation of the STAT3 Pathway in Cancer
Xiang, M. H. (2013) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 2
Novel mechanisms of Stat3 activation
Arulanandam, R. (2010) · QSpace (Queen's University Library) · Cited by 1
Zou, M., & Zeng, C. (2022) · Research Square · doi:10.21203/rs.3.rs-1586617/v1 · Cited by 1
Molecular mechanisms of apoptosis induced by dexamethasone in chronic lymphocytic leukemia
Baptista, G. M. L., & João, M. (2012) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Rare Bone Marrow Failure Conditions
Visconte, V., & Tiu, R. V. (2012) · Wiley eBooks · doi:10.1002/9781118464557.ch46
Signal Transducer and Activator of Transcription 3 (STAT3) and Trophoblast Invasion
Js, F., Poehlmann, T. G., Suman, P., Sk, G., Schleußner, E., & Markert, U. R. (2007) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 2
Bewry, N. N. (2009) · Digital Commons - University of South Florida (University of South Florida)
Mechanisms of Stem Cell Regulation in Medulloblastoma
Yoo, R. (2013) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Le myélome multiple : de la pathogenèse à la chimiorésistance
Hamouda, M. A. (2015) · theses.fr (ABES) · doi:10.70675/6f6e7e9fz1dd8z46d4zba0dzd2ee9237fa3b
Large granular lymphocyte leukemia: clinical background, molecular pathogenesis and treatment
LeBlanc, F., & Loughran, T. P. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1062362
“Dysregulated JAK/STAT signaling and constitutive STAT3 activation has been illustrated as a unifying pathogenetic feature in LGL leukemia [30,31].”
BackgroundSelf-citationRole of caveolin-1 in the proliferation of solid tumours in vitro
Pancotti, F. (2011) · Europe PMC (PubMed Central) · doi:10.6092/unibo/amsdottorato/3313
Nair, R. R., Gebhard, A. W., & Hazlehurst, L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_3
Drug discovery using the regulation of gene expression
St‐Pierre, Y. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.7.987
Apoptosis of Hypothalamic Neurosecretory Cells in Stress and Aging: The Role of Immunomodulators
Бажанова, Е. Д. (2013) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-013-9883-0
“CONCLUSIONS Data reported by many authors show that interferon alpha is actively involved in the process of programmed cell death [10, 22], while there are virtually no data on the involvement of cycloferon in controlling apoptosis.”
Regulation of neutrophil apoptosis by cytokines: Role of IAP family
Sakamoto, E., Kato, T., Hato, F., & Kitagawa, S. (2005) · Inflammation and Regeneration · doi:10.2492/jsir.25.525
Barry, S. P. (2009) · UCL Discovery (University College London)
Tees, M. T., Whitehurst, M., & Sokol, L. (2014) · International Journal of Hematologic Oncology · doi:10.2217/ijh.14.42
NDRG2 Expression Increases Apoptosis Induced by Doxorubicin in Malignant Breast Caner Cells
Kim, M.-J., Kang, K., Yang, Y. D., & Lim, J. (2009) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2009.17.4.370
“…of constitutive STAT3 activation in diverse tumor cell lines, by the blocking of tyrosine kinase signaling using small-molecule inhibitors, has been repeatedly associated with growth suppression and induction of cell death (Epling-Burnette et al., 2001; Garcia et al., 2001; Aggarwal et al., 2006).”
BackgroundThe Jak-Stat Pathway of Cytokine Signaling
Croker, B. A., & Nicola, N. A. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-747-5_3
Drug Discovery Approaches Targeting the JAK/STAT Pathway
Seidel, H. M., & Rosen, J. (2003) · Springer eBooks · doi:10.1007/978-94-017-3000-6_45
The role of parallel signaling pathways in maintaining lymphoid cell survival
Nagy, Z. S., & Kirken, R. A. (2002)
Prevention and Treatment of Head and Neck Cancer with Natural Compound Inhibitors of STAT3
Leeman‐Neill, R. J. (2008) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Involvement of transcription factors in acute pancreatitis
Shigekawa, M., & Takehara, T. (2014) · Suizo · doi:10.2958/suizo.29.38
Untersuchungen zur Prozessierung und
Pfreundschuh, M. G. (2009)
The Discovery and Development of Ruxolitinib for the Treatment of Myelofibrosis
Vaddi, K. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624202-00419
Wang, L. R. N. (2004) · Common Library Network (Der Gemeinsame Bibliotheksverbund)
Thiesen, H., Burger, R., Horn, F., Brocke-Heidrich, K., Kretzschmar, A. K., Pfeifer, G., Henze, C., & Löffler, D. (2013)
Rare Bone Marrow Failure Conditions
Duffield, A. S., & Dezern, A. E. (2017) · Wiley eBooks · doi:10.1002/9781119196235.ch54
Design and Synthesis of New Scaffolds for Stat5 Inhibition
Brown, C. E. (2013) · TSpace (University of Toronto)
The Role of STAT3 in the Pathogenesis of Chronic Lymphocytic Leukaemia
Brophy, S. (2018) · Trinity's Access to Research Output (TARA) (Trinity College Dublin)
Wang, S. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-20279-2_11
STAT3β is a tumor suppressor in acute myeloid leukemia
Aigner, P. (2019) · Intrinsic Activity · doi:10.25006/ia.7.s1-a3.3
Role of Heat Shock Protein 90 in Mammary Tumorigenesis
Kumar, B. V. S., Gopal, P. K., & Verma, R. (2019) · Heat shock proteins · doi:10.1007/978-3-030-23158-3_5
Herzberg, C. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7706
Wang, X., Wang, X., Zhang, L., Zhang, Y., Wang, F., Lü, Y., Zhang, W., & Wu, J. (2017) · PubMed Central
T-Cell Large Granular Lymphocytic Leukemia Involving the Liver and Spleen
Zhang, L., Chen, L., & Alkan, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-37708-3_10
Large Granular Lymphocyte Leukemia
Teramo, A., Vicenzetto, C., Barilà, G., Calabretto, G., Gasparini, V. R., Semenzato, G., & Zambello, R. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-55989-2_15
Phenocopies of inborn errors of immunity
Fekrvand, S., Abolhassani, H., Yazdani, R., & Döffinger, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821028-4.00009-9 · Cited by 2
Early Changes in Gene Expression Profiles in AML Patients During Induction ChemotherapyPreprint
Falk, I. J., Sundkvist, M., Björn, N., Gréen, H., & Lotfi, K. (2021) · Research Square · doi:10.21203/rs.3.rs-643327/v1
Molecular signaling and its role in drug resistance in hepatocellular carcinomas
Rasool, F., Kumar, B., Sharma, D., & Magani, S. K. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98807-0.00006-5
Phenocopies of Inborn Errors of Immunity
Oksenhendler, É. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00199-3
Early Changes in Gene Expression Profiles in AML Patients During Induction ChemotherapyPreprint
Falk, I. J., Sundkvist, M., Björn, N., Gréen, H., & Lotfi, K. (2021) · Research Square · doi:10.21203/rs.3.rs-643327/v2
Metadata
- Authors
- Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., Jove, R., & Loughran, T. P.
- Affiliations
- University of South Florida (US)
- National Taiwan University (TW)
- Ionis Pharmaceuticals (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2001-02-01
- Volume
- 107
- Issue
- 3
- Pages
- 351-362
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC199188
- OpenAlex
- W2041204531
- Cited by
- 633
- References
- 60
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 14 · 2023: 20 · 2022: 25 · 2021: 26 · 2020: 31 · 2019: 22 · 2018: 14 · 2017: 27 · 2016: 15 · 2015: 27 · 2014: 46 · 2013: 31 · 2012: 35
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Moffitt Cancer Center
- National Institutes of Health (5r21ca078724-02)
- National Cancer Institute (R01CA055652, CA-55652, CA78724)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- large granular lymphocyte leukemia, STAT3 signaling, apoptosis, Mcl-1, Fas resistance, AG490, antisense oligonucleotides, Bcl-2 family proteins, v-Src
- MeSH terms
- Cell Line, DNA-Binding Proteins, Enzyme Inhibitors, Gene Expression Regulation, Humans, Leukemia, Neoplasm Proteins, Phosphorylation, Tumor Cells, Cultured, Blotting, Western, Signal Transduction, Trans-Activators, Oncogene Protein pp60(v-src), Apoptosis, CD8-Positive T-Lymphocytes, Proto-Oncogene Proteins c-bcl-2, Dimerization, Tyrphostins, STAT3 Transcription Factor, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.